A greater awareness of the high mortality associated with nonamyloid forms of restrictive cardiomyopathy as well as ATTR-CM should prompt early consideration of pharmacological therapies such as mineralocorticoid receptor antagonists and SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is restrictive cardiomyopathy.